Please login to the form below
small cell lung cancer
This page shows the latest small cell lung cancer news and features for those working in and with pharma, biotech and healthcare.
Roche undercuts price of Bayer cancer drug after winning FDA approval
The approval clears Roche’s Rozlytrek (entrectinib) for use in adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC) and people aged 12 and over with solid tumours that ... Both drugs have proven to be highly effective in a small
Latest news
-
Tagrisso tops rival drugs on survival in first-line lung cancer
Takes fight to Pfizer's Vizimpro. AstraZeneca has the improvement in overall survival (OS) it needed for lung cancer therapy Tagrisso (osimertinib), as it tries to double down on its use ... Updated results from the FLAURA trial show that Tagrisso
-
Keytruda now available for untreated metastatic lung cancer patients via Cancer Drugs Fund
This follows prior approval from cost-effective watchdog NICE, which green-lit Keytruda for use in more than 3, 000 non-small cell lung cancer (NSCLC) patients. ... Meindert Boysen, director, NICE Centre for Health Technology Evaluation. “The committee
-
Triplet approvals for myeloma boost Celgene in Q2
Abraxane is enjoying a sales surge thanks to its use in combination with cancer immunotherapies in indications like non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC), according ... CAR-T therapy liso-cel (lisocabtagene maraleucel
-
CHMP backs Bayer’s tumour-agnostic drug Vitrakvi
Among these, Roche got the nod for a new indication for its cancer immunotherapy Tecentriq (atezolizumab) in non-small cell lung cancer, namely use in combination with chemotherapy (carboplatin/nab-paclitaxel) ... Merck picked up another positive opinion
-
Opdivo trial overshadows BMS financial results
driver Opdivo in lung cancer. ... BMS has been desperate to come up with an Opdivo (nivolumab) study that can expand use of the drug into first-line non-small cell lung cancer (NSCLC), a category comprehensively
More from news
Approximately 3 fully matching, plus 574 partially matching documents found.
Latest Intelligence
-
Immuno-oncology in 2019: the rapid evolution continues
It sealed its dominance last year with a string of successful endpoint-hitting trials, most especially in non- small cell lung cancer (NSCLC). ... Keytruda extends its lead. Keytruda established itself as the new standard for first-line treatment of
-
Is China ready for a pharmaceutical gold rush?
Bristol-Myers Squibb’s (BMS)’s Opdivo (nivolumab) was approved for the treatment of non-small cell lung cancer (NSCLC) in June. ... For patients with previously chemo-treated advanced non-small cell lung cancer, Opdivo reduced the risk of death in
-
China: AstraZeneca’s new engine for growth and innovation
There is a good reason why Tagrisso was chosen for the fast track – the drug is for patients with epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung ... Its Imfinzi has secured the first-ever US and EU approval in
-
Chinese biotech’s global ambitions
has just achieved a landmark approval in China for its own ‘home-grown’ cancer medicine. ... Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal
-
Cancer immunotherapy: What's on the horizon?
had transformative results in some diseases such as melanoma, non-small cell lung cancer and bladder cancer – among others. ... Non-small cell lung cancer (NSCLC) is a prime example of the impact the new PD-(L) 1 drugs can have.
More from intelligence
Approximately 0 fully matching, plus 21 partially matching documents found.
Latest appointments
-
Merck appoints ex-Pfizer exec as global head of oncology
In this role, she will be responsible for defining the pharmaceutical company's integrated global oncology strategies and delivering therapeutic launches, including the commercial launch of Avelumab, a non-small cell ... lung cancer therapy, which is
-
BIND Therapeutics appoints Andrew Hirsch as permanent CEO
Its lead compound, BIND-014, is currently in phase II clinical trials for KRAS-mutant and squamous histology non-small cell lung cancer.
-
Charles Morris appointed chief development officer at ImmunoGen
Dr Morris, who joins from Allos Therapeutics, will oversee all aspects of product development for the US cancer-focused biotech. ... Its pipeline includes the investigational compounds IMGN901 - in phase II testing for the treatment of small-cell lung
-
Axelar appoints Carl Harald Janson as CEO
Takes control as company prepares to take novel cancer drug to proof-of-concept. ... The biotech is currently running a randomised phase II clinical trial with AXL1717 in non-small cell lung cancer (NSCLC) patients, while a first-in-man phase I/II
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Therapy Watch expands oncology and IBD portfolios
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and
-
Therapy Watch expands its oncology portfolio
This month Therapy Watch Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). ... Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL),
-
How pembrolizumab will change the management of advanced lung cancer
The results of the Phase III KEYNOTE-024 trial of pembrolizumab for non-small cell lung cancer (NSCLC) were presented by VJOncology Editorial Board Member Dr Martin Reck of LungenClinic Grosshansdorf. ... He explains that “this data will completely
-
A stumble, but not a fall – what’s next for Opdivo?
In this manner, it can crucially target several cancers, a property that was successfully exploited by BMS and resulted in securing FDA nods for treating non-small cell lung cancer (NSCLC) ... and renal cell carcinoma (kidney cancer).
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Featured jobs
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- Account Director, Healthcare Communications
-
Salary TBC
- Account Director - Medical Communications - London / South East
-
Excellent Salary and Benefits on offer
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
-
Account Director – UK Office
-
Excellent salary and benefits
- FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...
-
Excellent Daily Rate
- Account Director – London based Medical Communications Agency
-
Excellent Remuneration Package
Subscribe to our email news alerts
- The relevance of patient perspectives to value
- Sanofi patent case win holds off generic rivals for key cancer drug
- Leo Pharma to market AstraZeneca’s brodalumab outside Europe
- Regeneron scores positive data in phase 3 cholesterol trial
- Roche undercuts price of Bayer cancer drug after winning FDA approval
- Putting our core values into practice at the Porterhouse summer social
PMHub
Kendle Healthcare
Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...
Latest intelligence
- The relevance of patient perspectives to value
- Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
- How is the NHS Long-term Plan being put into action?
- Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
- The evolution of real-world studies
- How industry and regulators are using real-world data...
Quick links
Infographics
